GB9624456D0 - Assay method - Google Patents

Assay method

Info

Publication number
GB9624456D0
GB9624456D0 GBGB9624456.1A GB9624456A GB9624456D0 GB 9624456 D0 GB9624456 D0 GB 9624456D0 GB 9624456 A GB9624456 A GB 9624456A GB 9624456 D0 GB9624456 D0 GB 9624456D0
Authority
GB
United Kingdom
Prior art keywords
assay method
epitopes
esat
vaccines
provision
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9624456.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10803428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB9624456(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB9624456.1A priority Critical patent/GB9624456D0/en
Publication of GB9624456D0 publication Critical patent/GB9624456D0/en
Priority to AU50632/98A priority patent/AU728357C/en
Priority to DE69737956T priority patent/DE69737956T2/en
Priority to DK97913336T priority patent/DK0941478T4/en
Priority to DK01109298T priority patent/DK1152012T3/en
Priority to PCT/GB1997/003222 priority patent/WO1998023960A1/en
Priority to AT97913336T priority patent/ATE213068T1/en
Priority to ES97913336T priority patent/ES2172773T5/en
Priority to EP01109298A priority patent/EP1152012B1/en
Priority to JP52441098A priority patent/JP4094674B2/en
Priority to DE69710360T priority patent/DE69710360T3/en
Priority to CA002272881A priority patent/CA2272881C/en
Priority to AT01109298T priority patent/ATE368052T1/en
Priority to EP97913336A priority patent/EP0941478B2/en
Priority to US09/308,725 priority patent/US7575870B1/en
Priority to US12/510,594 priority patent/US8617821B2/en
Priority to US14/090,221 priority patent/US9360480B2/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to the identification of CD8<+> T cell epitopes in the ESAT-6 protein of Mycobacterium tuberculosis and the use of peptides containing such epitopes in the provision of vaccines.
GBGB9624456.1A 1996-11-25 1996-11-25 Assay method Pending GB9624456D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB9624456.1A GB9624456D0 (en) 1996-11-25 1996-11-25 Assay method
AT01109298T ATE368052T1 (en) 1996-11-25 1997-11-25 CD8 TUBERCULOSIS VACCINES
EP97913336A EP0941478B2 (en) 1996-11-25 1997-11-25 Assay method for peptide specific t-cells
ES97913336T ES2172773T5 (en) 1996-11-25 1997-11-25 DOSAGE PROCEDURE OF SPECIFIC LYMPHOCYTES FOR A PEPTIDE.
DE69710360T DE69710360T3 (en) 1996-11-25 1997-11-25 ASSAY PROCEDURE FOR PEPTIDE-SPECIFIC T CELLS
DK97913336T DK0941478T4 (en) 1996-11-25 1997-11-25 Assay method for peptide-specific T cells
DK01109298T DK1152012T3 (en) 1996-11-25 1997-11-25 tuberculosis Vaccines
PCT/GB1997/003222 WO1998023960A1 (en) 1996-11-25 1997-11-25 Assay method for peptide specific t-cells
AT97913336T ATE213068T1 (en) 1996-11-25 1997-11-25 TESTING METHODS FOR PEPTIDE-SPECIFIC T CELLS
AU50632/98A AU728357C (en) 1996-11-25 1997-11-25 Assay method for peptide specific T-cells
EP01109298A EP1152012B1 (en) 1996-11-25 1997-11-25 CD8 based vaccine against tuberculosis
JP52441098A JP4094674B2 (en) 1996-11-25 1997-11-25 Method for assaying peptide-specific т cells
DE69737956T DE69737956T2 (en) 1996-11-25 1997-11-25 CD8 tuberculosis vaccines
CA002272881A CA2272881C (en) 1996-11-25 1997-11-25 Assay method for peptide specific t-cells
US09/308,725 US7575870B1 (en) 1996-11-25 2000-01-13 Assay method for peptide specific T-cells
US12/510,594 US8617821B2 (en) 1996-11-25 2009-07-28 Assay method for peptide specific T-cells
US14/090,221 US9360480B2 (en) 1996-11-25 2013-11-26 Assay method for peptide specific T-cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9624456.1A GB9624456D0 (en) 1996-11-25 1996-11-25 Assay method

Publications (1)

Publication Number Publication Date
GB9624456D0 true GB9624456D0 (en) 1997-01-15

Family

ID=10803428

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9624456.1A Pending GB9624456D0 (en) 1996-11-25 1996-11-25 Assay method

Country Status (11)

Country Link
US (3) US7575870B1 (en)
EP (2) EP1152012B1 (en)
JP (1) JP4094674B2 (en)
AT (2) ATE368052T1 (en)
AU (1) AU728357C (en)
CA (1) CA2272881C (en)
DE (2) DE69737956T2 (en)
DK (2) DK1152012T3 (en)
ES (1) ES2172773T5 (en)
GB (1) GB9624456D0 (en)
WO (1) WO1998023960A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
DK1144447T3 (en) 1998-11-04 2010-02-08 Isis Innovation Dianostic tuberculosis test
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
GB0006692D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Epitopes
WO2001078775A2 (en) * 2000-04-12 2001-10-25 Wisconsin Alumni Research Foundation A method for making an hiv vaccine
WO2002054072A2 (en) 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
DE10125730A1 (en) * 2001-05-17 2002-11-21 A I D Autoimmun Diagnostika Gm Detecting pathogens or cellular products induced by them, useful particularly for diagnosis of subacute spongiform encephalopathy
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
WO2005025497A2 (en) * 2003-09-05 2005-03-24 Genencor International, Inc. Hpv cd8+ t-cell epitopes
ITRM20040091A1 (en) * 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie QUICK IMMUNOLOGICAL TEST FOR DIAGNOSIS AND MONITORING OF TUBERCULAR INFECTION.
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
JP5946231B2 (en) 2004-04-28 2016-07-05 ビーティージー・インターナショナル・リミテッド Epitopes associated with celiac disease
WO2006009838A2 (en) * 2004-06-17 2006-01-26 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
GB0605474D0 (en) * 2006-03-17 2006-04-26 Isis Innovation Clinical correlates
GB0619853D0 (en) * 2006-10-06 2006-11-15 Oxford Immunotec Ltd Preparation method
DE102007052517A1 (en) 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh ELISPOT process with two filter systems
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
EP2385371B1 (en) 2008-09-22 2014-10-22 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
WO2011063283A2 (en) 2009-11-20 2011-05-26 Oregon Health & Science University Methods for detecting a mycobacterium tuberculosis infection
IT1403092B1 (en) 2010-12-01 2013-10-04 Univ Degli Studi Modena E Reggio Emilia METHOD FOR DIAGNOSIS AND / OR MONITORING OF MUCORMICOSIS.
US9078634B2 (en) 2011-01-27 2015-07-14 Cryosa, Llc Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues
FR2983213B1 (en) 2011-11-30 2015-03-06 Commissariat Energie Atomique METHOD FOR REAL-TIME MEASUREMENT OF INDIVIDUAL SECRETIONS OF A CELL
GB201122297D0 (en) 2011-12-23 2012-02-01 Retroscreen Virology Ltd Vaccine - screening method
EP2795321A2 (en) * 2011-12-23 2014-10-29 Retroscreen Virology Ltd Vaccine - screening method
WO2013106338A1 (en) 2012-01-12 2013-07-18 Mayo Foundation For Medical Education And Research Detecting latent tuberculosis infections
MX2014011484A (en) * 2012-03-23 2015-09-23 Esteve Labor Dr Method for monitoring hiv specific t cell responses.
US10401360B2 (en) 2013-04-29 2019-09-03 Mayo Foundation For Medical Education And Research Flow cytometry assay methods
EP3134737A4 (en) 2014-04-24 2018-01-17 Immusant Inc. Methods of diagnosis and treatment of celiac disease in children
EP3200736B8 (en) 2014-10-01 2020-06-17 CryOSA, Inc. Apparatus for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues
EP3221344A2 (en) 2014-11-21 2017-09-27 Immusant Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
FR3033333A1 (en) 2015-03-06 2016-09-09 Commissariat Energie Atomique METHOD AND DEVICE FOR REAL-TIME DETECTION OF A SECRETED COMPOUND AND THE SECRETORY TARGET AND USES THEREOF
CA3059408A1 (en) 2016-09-22 2018-04-12 Pace Diagnostics, Inc Mycobacterium tuberculosis proteins in diagnostic assays and devices for tuberculosis detection and diagnosis
US10245320B2 (en) 2016-09-30 2019-04-02 Enzo Biochem, Inc. Immunomodulatory pharmaceutical compositions and methods of use thereof
ES2950436T3 (en) 2016-12-14 2023-10-10 Becton Dickinson Co Methods and compositions to obtain an assessment of tuberculosis in a subject
WO2019018607A1 (en) 2017-07-20 2019-01-24 Enzo Biochem, Inc. Immunomodulatory compositions and methods of use thereof
KR102182555B1 (en) * 2019-03-14 2020-11-24 한국과학기술연구원 Platform of discovery of cancer therapeutic antigen for activation of T cell-mediated immune response
CN111856020B (en) * 2020-06-19 2022-09-27 南方医科大学南方医院 Hepatitis B Virus (HBV) specific T cell detection method and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU595021B2 (en) 1986-03-06 1990-03-22 Commonwealth Scientific And Industrial Research Organisation In vitro assay for detecting cell-mediated immune responses
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
DK79893D0 (en) 1993-07-02 1993-07-02 Statens Seruminstitut NEW VACCINE
US20020136733A1 (en) 1994-03-31 2002-09-26 Hill Adrian Vivian Sinton Malaria peptides
WO1997000067A1 (en) * 1995-06-15 1997-01-03 University Of Victoria Innovation And Development Mycobacterium tuberculosis dna sequences encoding immunostimulatory peptides
DE19525784A1 (en) 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreactive peptides from human glutamine decarboxylase (GAD)
US6410252B1 (en) 1995-12-22 2002-06-25 Case Western Reserve University Methods for measuring T cell cytokines
US5939281A (en) 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
GB9624456D0 (en) * 1996-11-25 1997-01-15 Isis Innovation Assay method
DK1144447T3 (en) * 1998-11-04 2010-02-08 Isis Innovation Dianostic tuberculosis test
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
WO2002054072A2 (en) 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
GB0215710D0 (en) * 2002-07-05 2002-08-14 Isis Innovation Diagnostic method

Also Published As

Publication number Publication date
ES2172773T3 (en) 2002-10-01
DK1152012T3 (en) 2007-11-26
DK0941478T4 (en) 2007-10-08
DK0941478T3 (en) 2002-07-01
JP2001505568A (en) 2001-04-24
ATE213068T1 (en) 2002-02-15
US20140087399A1 (en) 2014-03-27
US20100203568A1 (en) 2010-08-12
DE69737956D1 (en) 2007-09-06
DE69710360T2 (en) 2002-11-14
ES2172773T5 (en) 2008-01-16
EP1152012A1 (en) 2001-11-07
CA2272881A1 (en) 1998-06-04
EP0941478B1 (en) 2002-02-06
DE69737956T2 (en) 2008-04-17
ATE368052T1 (en) 2007-08-15
AU5063298A (en) 1998-06-22
DE69710360D1 (en) 2002-03-21
AU728357C (en) 2001-11-01
EP0941478A1 (en) 1999-09-15
JP4094674B2 (en) 2008-06-04
CA2272881C (en) 2007-10-09
EP0941478B2 (en) 2007-06-06
US8617821B2 (en) 2013-12-31
US7575870B1 (en) 2009-08-18
DE69710360T3 (en) 2008-01-17
AU728357B2 (en) 2001-01-04
WO1998023960A1 (en) 1998-06-04
US9360480B2 (en) 2016-06-07
EP1152012B1 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
GB9624456D0 (en) Assay method
SG49008A1 (en) Hla-a2.1 binding peptides and their uses
IL106610A0 (en) Hla binding peptides and their uses
HUP0101521A3 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
EP0907370A4 (en) Hla-a2.1 binding peptides and their uses
NZ301290A (en) Mycobacterial proteins, micro-organisms producing same and vaccines thereof
TR199701252T1 (en) Networks containing a saponin and a sterol.
ATE512666T1 (en) HLA-BINDING PEPTIDES AND THEIR USES
ATE87655T1 (en) MARKERS OF T-CELL ACTIVATION.
SG52342A1 (en) T cell antigen receptor v region protein and methos of preparation thereof
GB9409985D0 (en) Vaccine against mycobacterial infections
EP1214088A4 (en) Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
EP1089757A4 (en) Hla binding peptides and their uses
BR9407357A (en) New tripeptides usable in cns and immune therapy
EP0317279A3 (en) Peptides for use in the purification of factor viii
CA2140091A1 (en) Peptides and antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2
WO1997039020A3 (en) Antigenic sequences of a sperm protein and immunocontraceptive methods
AU7732894A (en) Graves&#39; ophthalmopathy associated antibodies, graves&#39; ophthalmopathy orbital antigen, and methods of use thereof
ZA9710584B (en) Peptides antibodies vaccines and uses thereof